These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 24890620)

  • 1. Authors' reply to Comment on "No impact of interleukin-28B polymorphisms on spontaneous or drug-induced hepatitis delta virus clearance" [Dig. Liver Dis.2014;46:348-52].
    Visco-Comandini U; Lapa D; Taibi C; Angeletti C
    Dig Liver Dis; 2014 Aug; 46(8):762. PubMed ID: 24890620
    [No Abstract]   [Full Text] [Related]  

  • 2. Comment on "No impact of interleukin-28B polymorphisms on spontaneous or drug-induced hepatitis delta virus clearance" by Ubaldo Visco-Comandini et al. [Dig. Liver Dis. 2014;46:348-52].
    Keshvari M; Sharafi H; Alavian SM
    Dig Liver Dis; 2014 Aug; 46(8):761-2. PubMed ID: 24815081
    [No Abstract]   [Full Text] [Related]  

  • 3. No impact of interleukin-28B polymorphisms on spontaneous or drug-induced hepatitis delta virus clearance.
    Visco-Comandini U; Lapa D; Taibi C; Angeletti C; Capobianchi MR; Garbuglia AR
    Dig Liver Dis; 2014 Apr; 46(4):348-52. PubMed ID: 24387833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can We Predict Sustained Virologic Response to Interferon α Therapy in Patients With Chronic Hepatitis Delta Virus Infection?
    Scholtès C; Kumar R; Zoulim F
    Clin Gastroenterol Hepatol; 2015 Dec; 13(13):2350-2. PubMed ID: 26254201
    [No Abstract]   [Full Text] [Related]  

  • 5. Hepatitis D virus-specific cytokine responses in patients with chronic hepatitis delta before and during interferon alfa-treatment.
    Grabowski J; Yurdaydìn C; Zachou K; Buggisch P; Hofmann WP; Jaroszewicz J; Schlaphoff V; Manns MP; Cornberg M; Wedemeyer H;
    Liver Int; 2011 Oct; 31(9):1395-405. PubMed ID: 21762356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current management of delta hepatitis.
    Rizzetto M
    Liver Int; 2013 Feb; 33 Suppl 1():195-7. PubMed ID: 23286865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome.
    Keskin O; Wedemeyer H; Tüzün A; Zachou K; Deda X; Dalekos GN; Heidrich B; Pehlivan S; Zeuzem S; Yalçın K; Gürel S; Tabak F; Idilman R; Bozkaya H; Manns M; Yurdaydin C
    Clin Gastroenterol Hepatol; 2015 Dec; 13(13):2342-49.e1-2. PubMed ID: 26044319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative analysis of hepatitis D virus RNA and hepatitis B surface antigen serum levels in chronic delta hepatitis improves treatment monitoring.
    Manesis EK; Schina M; Le Gal F; Agelopoulou O; Papaioannou C; Kalligeros C; Arseniou V; Manolakopoulos S; Hadziyannis ES; Gault E; Koskinas J; Papatheodoridis G; Archimandritis AJ
    Antivir Ther; 2007; 12(3):381-8. PubMed ID: 17591028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resolution of chronic hepatitis delta infection after five years of peginterferon-adefovir: lessons from a case report.
    Brichler S; Setshedi M; Renou C
    Clin Res Hepatol Gastroenterol; 2013 Jun; 37(3):e81-4. PubMed ID: 23433964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Letter: the potential success of long-term therapy of chronic delta hepatitis with peginterferon alfa--authors' reply.
    Koh C; Heller T
    Aliment Pharmacol Ther; 2015 Mar; 41(6):595-6. PubMed ID: 25659215
    [No Abstract]   [Full Text] [Related]  

  • 11. Optimized HBsAg titer monitoring improves interferon therapy in patients with chronic hepatitis delta.
    Ouzan D; Pénaranda G; Joly H; Halfon P
    J Hepatol; 2013 Jun; 58(6):1258-9. PubMed ID: 23318602
    [No Abstract]   [Full Text] [Related]  

  • 12. Resolution of chronic hepatitis Delta after 1 year of combined therapy with pegylated interferon, tenofovir and emtricitabine.
    Mansour W; Ducancelle A; Le Gal F; Le Guillou-Guillemette H; Abgueguen P; Pivert A; Calès P; Gordien E; Lunel F
    J Clin Virol; 2010 Jan; 47(1):97-9. PubMed ID: 19914127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of delta (type D) hepatitis].
    Pol S
    Gastroenterol Clin Biol; 2005 Apr; 29(4):384-7. PubMed ID: 15864199
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up.
    Castelnau C; Le Gal F; Ripault MP; Gordien E; Martinot-Peignoux M; Boyer N; Pham BN; Maylin S; Bedossa P; Dény P; Marcellin P; Gault E
    Hepatology; 2006 Sep; 44(3):728-35. PubMed ID: 16941695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiviral therapy of hepatitis delta virus infection - progress and challenges towards cure.
    Wranke A; Wedemeyer H
    Curr Opin Virol; 2016 Oct; 20():112-118. PubMed ID: 27792905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta.
    Heidrich B; Yurdaydın C; Kabaçam G; Ratsch BA; Zachou K; Bremer B; Dalekos GN; Erhardt A; Tabak F; Yalcin K; Gürel S; Zeuzem S; Cornberg M; Bock CT; Manns MP; Wedemeyer H;
    Hepatology; 2014 Jul; 60(1):87-97. PubMed ID: 24585488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of pegylated interferon-α treatment for 24 months in chronic delta hepatitis and predictors of response.
    Karaca C; Soyer OM; Baran B; Ormeci AC; Gokturk S; Aydin E; Evirgen S; Akyuz F; Demir K; Besisik F; Kaymakoglu S
    Antivir Ther; 2013; 18(4):561-6. PubMed ID: 22976528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exacerbation of chronic hepatitis D during interferon alpha administration.
    Crosignani A; Invernizzi P; Ferrari R; Manzin A; Bruno S; Zuin M; Bianchi FB; Podda M
    Ital J Gastroenterol Hepatol; 1999; 31(1):66-9. PubMed ID: 10091106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta.
    Niro GA; Ciancio A; Gaeta GB; Smedile A; Marrone A; Olivero A; Stanzione M; David E; Brancaccio G; Fontana R; Perri F; Andriulli A; Rizzetto M
    Hepatology; 2006 Sep; 44(3):713-20. PubMed ID: 16941685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy of new therapies].
    Ongaro M; Spahr L; Giostra E; Negro F
    Rev Med Suisse; 2020 Sep; 16(704):1538-1543. PubMed ID: 32880108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.